KCIA
ACIU icon

Kingsbury Capital Investment Advisors’s AC Immune ACIU Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$86K Buy
27,291
+8,423
+45% +$26.5K 0.13% 71
2022
Q2 		$68K Sell
18,868
-107
-0.6% -$366 0.09% 86
2022
Q1 		$76K Buy
+18,975
New +$82.2K 0.08% 90

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Kingsbury Capital Investment Advisors's ACIU Position: Q3 2022 in Review

Kingsbury Capital Investment Advisors increased its AC Immune (ACIU) stake by 45% in Q3 2022, buying an estimated $26.5K and bringing the position to 27,291 shares worth $86K. The position accounts for 0.13% of the portfolio, ranked #71.

Kingsbury Capital Investment Advisors first reported a position in ACIU in Q1 2022 and has held it in 3 quarters since. 34 funds tracked by Wall St. Rank hold ACIU as of Q3 2022.

  • Kingsbury Capital Investment Advisors held 27,291 shares of AC Immune worth $86K as of Q3 2022.
  • Kingsbury Capital Investment Advisors bought 8,423 AC Immune shares in Q3 2022, an estimated $26.5K.
  • AC Immune made up 0.13% of Kingsbury Capital Investment Advisors's portfolio in Q3 2022, its #71 holding.
  • Kingsbury Capital Investment Advisors first reported a position in AC Immune in Q1 2022 and has held it in 3 quarters since.
  • 34 funds tracked by Wall St. Rank held AC Immune as of Q3 2022.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.